Roche grabs a re­myeli­na­tion MS drug from Ver­sant as the re­search team spins out in­to a $25M re­gen­er­a­tive med start­up

Near­ly 4 years af­ter Roche agreed to pay the re­search tab for a team of in­ves­ti­ga­tors at Ver­sant Ven­tures’ dis­cov­ery group In­cep­tion Sci­ences to see if they could come up with a vi­able, IND-ready com­pound to take in­to the clin­ic for re­myeli­na­tion work in mul­ti­ple scle­ro­sis, the phar­ma gi­ant has grabbed its star can­di­date. And the team they helped fund is now be­ing spun out in­to a start­up fo­cused on neu­rore­gen­er­a­tion with the bless­ings of Ver­sant and a com­mit­ment of $25 mil­lion to help fund their new, in­de­pen­dent ex­is­tence.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.